Regenity bioscience - FloodGate Medical

Engineering the future of regenerative medicine

About Us

As the global leader in regenerative medicine, Regenity delivers life-changing transformations. We create and build regenerative bioresorbable implants that make a material difference in the lives of patients. Our vertically integrated business model is highly customizable, so our cross-functional teams can support you from concept through commercialization—exactly where and when you need us. We bring together the environment and expertise to help you achieve superior product performance and cost-effective production at scale.

You can choose to partner with us through private label or custom development and manufacturing agreements. Whether you’re looking to collaborate on product development or outsource capabilities, we’ll tailor our support to meet your needs.

Look at the Leaders of Regenity

Shawn McCarthy

Chief Executive Officer

Peggy Hansen

General Manager, Contract Development + Manufacturing & Senior Vice President, Regulatory, Quality and Clinical Affairs

Jessica Swanson

Vice President of Marketing

Oystein Valberg

Chief Financial Officer

Aaron Kendrick

Senior Vice President Operations

Susan Miller

Head of Human Resources

Jim Pomeroy

Vice President, Quality and Regulatory Affairs

Bill Messer

Vice President of Commercial Operations

Product Portfolio

Fast-track your product pipeline with advanced therapeutic solutions that support the body’s natural ability to regenerate.

Our proprietary collagen and polymer-based products support the development of regenerative therapies for applications across a variety of clinical segments, including dental, orthopedic, sports medicine, neurosurgery, advanced wound care, and more.  All products meet required FDA and ISO compliance and manufacturing certifications for the highest level of biomaterial quality—supporting a clear path to successful commercialization.

We invite you to explore our private label products and discover how we can help you expand your offerings, accelerate time to market, and improve the lives of more patients.

Dental

Precision, state-of-the-art solutions for oral surgical repairs

Regenity is a trusted partner to the global dental community. Our private label collagen dental membranes, anorganic and synthetic bone graft substitutes, and collagen dental wound dressings help clinicians achieve precise repair and successful wound healing.

– Highly purified and biocompatible
– Differentiated by handling and resorption profile
– Products available in a variety of sizes, forms, and configurations

Nerve Repair

Flexible platforms for targeted nerve reconstruction and exceptional patient outcomes

Our proven xenograft peripheral nerve repair solutions give surgeons the flexibility to choose from diverse approaches including bridging, capping, and protecting damaged nerves. Available for various nerve injury types, they promote functional recovery, reduced scar formation, and neuroma prevention.

– Proprietary collagen-derived materials offer favorable profiles in terms of tissue support, guidance, and healing
– Resorbable, biocompatible, and semipermeable
– No harvest of autograft required; allows for a convenient single surgical procedure

Dural Repair & Closure

Innovative solutions for secure coverage, confident closure, and optimal tissue regeneration.

Regenity’s line of collagen dural repair products offer a variety of resorption times, surge strengths, and conformability levels to meet specific therapeutic applications and promote successful healing.

– Engineered for the protection, closure, and repair of dural defects
– Excellent CSF leak resistance
– Supports natural regeneration of native dural tissue

Spine & Orthopedics

Advanced solutions for reliable regeneration—trusted by orthopedic surgeons worldwide

Regenity’s xenograft mineral and collagen composite matrix bone graft substitutes promote successful tissue ingrowth and repair. We also offer resorbable collagen wraps to manage tendon injuries where there has been no substantial loss of tendon tissue. Our proprietary portfolio delivers excellent performance that improves efficiency and supports better patient recovery outcomes.

– Engineered to support tissue healing and regeneration
– Highly biocompatible
– Optimal resorption and remodeling

Company Spotlight Video

Highlights

Regenity Biosciences Announces New Allendale Campus, Fueled by Record Growth and an Expanding Product Pipeline

Regenity Biosciences today announced the signing of a lease on a new facility in Allendale, NJ. The announcement marks not just a physical expansion, but a reflection of the company’s accelerating momentum: Regenity products are now impacting more than 5 million patients annually, the company is actively launching new products across a growing pipeline, and its reach continues to expand into new markets globally.

Regenity Biosciences Strengthens Executive Leadership Team with Two Strategic Appointments, Advancing its Mission to Lead the Next Generation of Regenerative Devices

Regenity Biosciences, a global leader in regenerative medicine and contract development and manufacturing partner for the medical device industry, today announced two significant executive appointments that reflect the company’s accelerating growth trajectory and its commitment to building the leadership infrastructure necessary to scale its innovation platform. Effective today, Peggy Hansen has been promoted to Chief Innovation & Strategy Officer, and Aaron Kendrick has joined the company as Senior Vice President of Operations.

Regenity Biosciences receives strategic investment from Cinven, adding new partner alongside Linden Capital Partners

Transaction will establish partnership between Regenity, Cinven, and legacy investor Linden Capital Partners to support the Company’s next phase of growth

The investment, which is expected to support Regenity’s efforts to scale product development and delivery, comes as the Company looks to expand its manufacturing footprint

International private equity firm Cinven and Chicago-based Linden Capital Partners (‘Linden’) today announced that Cinven has agreed to make a strategic investment in Regenity Biosciences (‘Regenity’ or ‘the Company’), a global developer and manufacturer of bioresorbable technologies and Linden portfolio company. Financial terms were not disclosed.

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!